Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstract for Metastatic Uveal Melanoma at American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
27 avr. 2022 10h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10, a formulation of...